Jaguar Health, Inc. (JAGX)
Market Cap | 48.64M |
Revenue (ttm) | 9.76M |
Net Income (ttm) | -41.30M |
Shares Out | 276.22M |
EPS (ttm) | -1.79 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,775,898 |
Open | 0.171 |
Previous Close | 0.170 |
Day's Range | 0.166 - 0.191 |
52-Week Range | 0.051 - 1.220 |
Beta | 1.38 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 13, 2024 |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief o... [Read more]
Financial Performance
In 2023, Jaguar Health's revenue was $9.76 million, a decrease of -18.36% compared to the previous year's $11.96 million. Losses were -$41.30 million, -12.97% less than in 2022.
Financial StatementsNews
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient a...
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and de...
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse eve...
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN ...
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar He...
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN fo...
Jaguar Health Reports 2023 Financial Results
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approx...
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March ...
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (...
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the status of its listing with The Nasdaq Stock Ma...
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, C...
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug My...
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both shor...
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2...
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer...
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 4, 2024, the Company granted 7,500 restricted s...
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvil...
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support fo...
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
To register for the webinar, click here SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Mult...
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Qua...
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainabl...
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIR...
Jaguar Health's stock drops after results supporting ‘paramount' trial have not been received yet
Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarr...
Top Line Data for Jaguar Health's Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with re...
Jaguar Health Reports Third Quarter 2023 Financial Results
Net revenue increased 5% in Q3 2023 versus Q2 2023 Top line results expected before Thanksgiving for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related...